Early intervention services, patterns of prescription and rates of discontinuation of antipsychotic treatment in first-episode psychosis
Por:
Catalan, A, Garcia, L, Sanchez-Alonso, S, Gil, P, Diaz-Marsa, M, Olivares, J, Rivera-Baltanas, T, Perez-Martin, J, Torres, M, Ovejero, S, Tost, M, Berge, D, Rodriguez, A and Labad, J
Publicada:
1 dic 2021
Ahead of Print:
1 dic 2020
Resumen:
Aims: Non-compliance is still an important problem in psychotic patients. Although antipsychotic (AP) treatment leads to a decrease in psychotic relapses, there are no clear recommendations about how long treatment should be maintained after first-episode psychosis (FEP) and no indication of the rates and causes of treatment withdrawal in this group.
Methods: We evaluated a large sample of patients with FEP for 2 years to compare the time to all-cause treatment discontinuation of AP drugs and the time to the first relapse. We collected the sociodemographic and psychopathological characteristics of the sample. The number of relapses was also recorded.
Results: A total of 310 FEP patients were assessed across seven early intervention teams (mean age = 30.2 years; SD = 11.2). The most prevalent diagnosis at baseline was psychotic disorder not otherwise specified (36.1%), and the most commonly used APs were risperidone (26.5%) and olanzapine (18.7%). A lack of efficacy was the most frequent reason for the withdrawal of the first AP prescribed, followed by non-compliance. There were no differences in the relapse rates between different APs. Patients treated with long-acting injectable (LAI) APs presented less disengagement from services than patients treated with oral APs.
Conclusions: Although there were no differences between the different APs in terms of relapse rates, LAIs had higher retention rates than oral APs in early intervention services. Compliance is still an important issue in Psychiatry, so clinicians should use different strategies to encourage it, such as the use of LAI treatments.
Filiaciones:
Catalan, A:
Univ Basque Country, Basurto Univ Hosp, Fac Med & Odontol, Biocruces Bizkaia Hlth Res Inst,Mental Hlth Dept, Campus Leioa, Bizkaia, Spain
:
Hosp Univ San Juan, Dept Psychiat, Alicante, Spain
Univ Miguel Hernandez, Dept Clin Med, Edificio Muhammad Al Shafra, Alicante, Spain
Sanchez-Alonso, S:
Jimenez Diaz Fdn Hosp, Dept Psychiat, Madrid, Spain
Gil, P:
Bizkaia Mental Hlth Syst, Biocruces Bizkaia Hlth Res Inst, Early Intervent Serv, Mental Hlth Dept, Bilbao, Bizkaia, Spain
Diaz-Marsa, M:
Univ Hosp Clin San Carlos Madrid, Psychiat Dept, IDISSC, Madrid, Spain
Olivares, J:
Univ Vigo, Hosp Alvaro Cunqueiro, Galicia Hlth Res Inst CIBERSAM, Dept Psychiat,Translat Neurosci Grp, Vigo, Spain
Rivera-Baltanas, T:
Univ Vigo, Hosp Alvaro Cunqueiro, Galicia Hlth Res Inst CIBERSAM, Dept Psychiat,Translat Neurosci Grp, Vigo, Spain
:
Hosp Univ San Juan, Dept Psychiat, Alicante, Spain
Univ Miguel Hernandez, Dept Clin Med, Edificio Muhammad Al Shafra, Alicante, Spain
Torres, M:
Univ Basque Country, Basurto Univ Hosp, Fac Med & Odontol, Biocruces Bizkaia Hlth Res Inst,Mental Hlth Dept, Campus Leioa, Bizkaia, Spain
Ovejero, S:
Jimenez Diaz Fdn Hosp, Dept Psychiat, Madrid, Spain
Tost, M:
Univ Autonoma Barcelona, Dept Mental Hlth, Early Intervent Serv Psychosis,I3PT, CIBERSAM,Parc Tauli Hosp Univ,Dept Psychiat & For, Sabadell, Spain
Berge, D:
Inst Neuropsiquiatria & Adicc INAD, Parc Salut Mar, Barcelona, Spain
Fundacio Hosp Mar Med Res Inst IMIM, Barcelona, Spain
Ctr Invest Biomed Red, Area Salud Mental CIBERSAM, Madrid, Spain
Rodriguez, A:
Dept Psychiat, Parc Salut Mar, Barcelona, Spain
Labad, J:
Univ Autonoma Barcelona, Dept Mental Hlth, Early Intervent Serv Psychosis,I3PT, CIBERSAM,Parc Tauli Hosp Univ,Dept Psychiat & For, Sabadell, Spain
|